Paul Greenberg, managing principal and director of Analysis Group’s Health Care Practice, specialises in health economics, both in health outcomes research and in complex business litigation. He consults to pharmaceutical, biotechnology, and medical device companies concerning the health economics profiles of specific diseases and medical products. He has overseen cost-of-illness research relating to numerous physical and psychiatric disorders, as well as pharmacoeconomic assessments of the cost-effectiveness of drugs based on data gathered in clinical trials and administrative claims files.
Mr Greenberg’s health outcomes research has been published in leading medical, health economics and managed care journals. He draws upon the methodological tools and data sources commonly used in an outcomes research context to analyse problems that emerge in litigation involving healthcare products (eg, pharmaceuticals, biotechnology and medical devices). More specifically, Mr Greenberg’s experience includes performing economic analyses and presenting findings to US Attorney’s Office investigators in numerous cases with allegations of off-label promotion, kickback or pricing issues, in which Food, Drug and Cosmetic Act, False Claims Act or Anti-Kickback statute violations have been alleged. He has provided economic consulting support in connection with class certification, liability and damages in cases involving allegations of antitrust, product failure, product fraud or patent infringement.
Mr Greenberg has also provided strategic assistance to counsel at various key points in litigation, including pretrial discovery, settlement negotiations and trial preparation.